{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Protease+Inhibitor&page=9", "query": { "condition": "Protease Inhibitor", "page": 9 }, "page_size": 10 }, "pagination": { "page": 9, "page_size": 10, "total_count": 337, "total_pages": 34, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Protease+Inhibitor&page=10&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Protease+Inhibitor&page=8&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-11T09:00:50.027Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00002190", "title": "A Phase II Open-Label Exploratory Study of Saquinavir + Zidovudine + Lamivudine in HIV Infected Patients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "HIV Infections" ], "interventions": [ { "name": "Saquinavir", "type": "DRUG" }, { "name": "Lamivudine", "type": "DRUG" }, { "name": "Zidovudine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 30, "start_date": null, "completion_date": null, "has_results": false, "last_update_posted_date": "2005-06-24", "last_synced_at": "2026-10-11T09:00:50.027Z", "location_count": 3, "location_summary": "San Francisco, California • Sherman Oaks, California • New York, New York", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "Sherman Oaks", "state": "California" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00002190" }, { "nct_id": "NCT00016783", "title": "Stopping and Restarting Anti-HIV Drugs in Children and Adolescents With Low Blood Levels of HIV", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "HIV Infections" ], "interventions": [], "intervention_types": [], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "2 Years", "maximum_age": "21 Years", "sex": "ALL", "summary": "2 Years to 21 Years" }, "enrollment_count": 39, "start_date": null, "completion_date": "2006-10", "has_results": false, "last_update_posted_date": "2013-10-07", "last_synced_at": "2026-10-11T09:00:50.027Z", "location_count": 16, "location_summary": "Los Angeles, California • Denver, Colorado • Washington D.C., District of Columbia + 11 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Miami", "state": "Florida" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT00016783" }, { "nct_id": "NCT00000885", "title": "Treatment Success and Failure in HIV-Infected Subjects Receiving Indinavir in Combination With Nucleoside Analogs: A Rollover Study for ACTG 320", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "HIV Infections" ], "interventions": [ { "name": "Indinavir sulfate", "type": "DRUG" }, { "name": "Abacavir sulfate", "type": "DRUG" }, { "name": "Nelfinavir mesylate", "type": "DRUG" }, { "name": "Efavirenz", "type": "DRUG" }, { "name": "Levocarnitine", "type": "DRUG" }, { "name": "Adefovir dipivoxil", "type": "DRUG" }, { "name": "Lamivudine", "type": "DRUG" }, { "name": "Stavudine", "type": "DRUG" }, { "name": "Zidovudine", "type": "DRUG" }, { "name": "Didanosine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "16 Years", "maximum_age": null, "sex": "ALL", "summary": "16 Years and older" }, "enrollment_count": 440, "start_date": null, "completion_date": "2003-06", "has_results": false, "last_update_posted_date": "2021-10-28", "last_synced_at": "2026-10-11T09:00:50.027Z", "location_count": 52, "location_summary": "Birmingham, Alabama • Los Angeles, California • San Francisco, California + 32 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "San Jose", "state": "California" }, { "city": "Stanford", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00000885" }, { "nct_id": "NCT00014937", "title": "Simplified Drug Regimens for HIV Patients in ACTG 388 or Patients Who Responded to A First Potent Combination Regimen", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "HIV Infections" ], "interventions": [ { "name": "lopinavir/ritonavir", "type": "DRUG" }, { "name": "lamivudine/zidovudine", "type": "DRUG" }, { "name": "efavirenz", "type": "DRUG" }, { "name": "lamivudine", "type": "DRUG" }, { "name": "stavudine", "type": "DRUG" }, { "name": "zidovudine", "type": "DRUG" }, { "name": "didanosine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "13 Years", "maximum_age": null, "sex": "ALL", "summary": "13 Years and older" }, "enrollment_count": 240, "start_date": null, "completion_date": null, "has_results": false, "last_update_posted_date": "2013-07-29", "last_synced_at": "2026-10-11T09:00:50.027Z", "location_count": 32, "location_summary": "Los Angeles, California • Denver, Colorado • Farmington, Connecticut + 19 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "Denver", "state": "Colorado" }, { "city": "Farmington", "state": "Connecticut" }, { "city": "Miami", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT00014937" }, { "nct_id": "NCT00012519", "title": "Ritonavir and Indinavir in Children Failing Other Anti-HIV Treatment", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "HIV Infections" ], "interventions": [ { "name": "indinavir sulfate", "type": "DRUG" }, { "name": "ritonavir", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "2 Years", "maximum_age": "17 Years", "sex": "ALL", "summary": "2 Years to 17 Years" }, "enrollment_count": 29, "start_date": null, "completion_date": "2005-07", "has_results": false, "last_update_posted_date": "2021-11-01", "last_synced_at": "2026-10-11T09:00:50.027Z", "location_count": 11, "location_summary": "Washington D.C., District of Columbia • Gainesville, Florida • Jacksonville, Florida + 6 more", "locations": [ { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Gainesville", "state": "Florida" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Chicago", "state": "Illinois" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00012519" }, { "nct_id": "NCT00259727", "title": "The Study of HIV Protease Inhibitors and Their Effects on Glucose Metabolism", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Diabetes", "HIV Infections", "Insulin Resistance" ], "interventions": [], "intervention_types": [], "sponsor": "US Department of Veterans Affairs", "sponsor_class": "FED", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "72 Years", "sex": "ALL", "summary": "18 Years to 72 Years" }, "enrollment_count": 80, "start_date": "2006-01", "completion_date": "2008-09", "has_results": false, "last_update_posted_date": "2009-09-30", "last_synced_at": "2026-10-11T09:00:50.027Z", "location_count": 1, "location_summary": "San Francisco, California", "locations": [ { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00259727" }, { "nct_id": "NCT00084136", "title": "Prospective Evaluation of Anti-retroviral Combinations for Treatment Naive, HIV Infected Persons in Resource-limited Settings", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "HIV Infections" ], "interventions": [ { "name": "Atazanavir", "type": "DRUG" }, { "name": "Didanosine (enteric-coated)", "type": "DRUG" }, { "name": "Efavirenz", "type": "DRUG" }, { "name": "Emtricitabine", "type": "DRUG" }, { "name": "Emtricitabine/Tenofovir disoproxil fumarate", "type": "DRUG" }, { "name": "Lamivudine/Zidovudine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1571, "start_date": "2005-05", "completion_date": "2010-05", "has_results": true, "last_update_posted_date": "2018-10-10", "last_synced_at": "2026-10-11T09:00:50.027Z", "location_count": 27, "location_summary": "Los Angeles, California • Torrance, California • Denver, Colorado + 16 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Torrance", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "Honolulu", "state": "Hawaii" } ], "official_url": "https://clinicaltrials.gov/study/NCT00084136" }, { "nct_id": "NCT00040664", "title": "A Clinical Study Of An Investigational Regimen Including Marketed HIV Drugs In HIV-1 Pediatric Subjects Ages 2-18 Years", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "HIV Infection" ], "interventions": [ { "name": "ritonavir", "type": "DRUG" }, { "name": "fosamprenavir", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "ViiV Healthcare", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "2 Years", "maximum_age": "18 Years", "sex": "ALL", "summary": "2 Years to 18 Years" }, "enrollment_count": 69, "start_date": "2002-07", "completion_date": "2008-10", "has_results": true, "last_update_posted_date": "2017-03-03", "last_synced_at": "2026-10-11T09:00:50.027Z", "location_count": 17, "location_summary": "Birmingham, Alabama • Los Angeles, California • Jacksonville, Florida + 13 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Los Angeles", "state": "California" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Tampa", "state": "Florida" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT00040664" }, { "nct_id": "NCT00002236", "title": "A Study to Find the Best Dosing Schedule for Delavirdine, Zidovudine, and Indinavir in HIV-Positive Patients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "HIV Infections" ], "interventions": [ { "name": "Indinavir sulfate", "type": "DRUG" }, { "name": "Delavirdine mesylate", "type": "DRUG" }, { "name": "Zidovudine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pharmacia and Upjohn", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "14 Years", "maximum_age": null, "sex": "ALL", "summary": "14 Years and older" }, "enrollment_count": 32, "start_date": null, "completion_date": null, "has_results": false, "last_update_posted_date": "2005-06-24", "last_synced_at": "2026-10-11T09:00:50.027Z", "location_count": 6, "location_summary": "Los Angeles, California • San Francisco, California • New York, New York + 3 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "New York", "state": "New York" }, { "city": "Pittsburgh", "state": "Pennsylvania" }, { "city": "Memphis", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT00002236" }, { "nct_id": "NCT01859962", "title": "Study of PPI-668, BI 207127 and Faldaprevir, With and Without Ribavirin, in the Treatment of Chronic Hepatitis C", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Chronic Hepatitis C" ], "interventions": [ { "name": "PPI-668", "type": "DRUG" }, { "name": "BI 207127 Dose 1", "type": "DRUG" }, { "name": "BI 207127 Dose 2", "type": "DRUG" }, { "name": "Faldaprevir", "type": "DRUG" }, { "name": "Ribavirin", "type": "DRUG" }, { "name": "BI 207127 Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Presidio Pharmaceuticals, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 38, "start_date": "2013-05", "completion_date": "2014-12", "has_results": false, "last_update_posted_date": "2015-11-25", "last_synced_at": "2026-10-11T09:00:50.027Z", "location_count": 1, "location_summary": "San Francisco, California", "locations": [ { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01859962" } ] }